Skip to content
Menu

Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $9

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $11 to $9.

Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $11 to $9.

Read at benzinga.com

← All stock news